Company profile
Atea Pharmaceuticals, Inc.
NASDAQ:AVIRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BEMNIFOSBUVIR SULFATE | phase2 | — | 12 | completed, terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (33)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05904470 | phase2 | completed | 2023-05-30 | 2024-12-09 | Atea Pharmaceuticals, Inc. | A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV |
| NCT04877769 | phase1 | completed | 2021-04-25 | 2021-08-31 | Atea Pharmaceuticals, Inc. | Bronchopulmonary PK of AT-527 (R07496998) |
| NCT06868264 | phase3 | active_not_recruiting | 2025-04-07 | 2026-09-01 | Atea Pharmaceuticals, Inc. | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV |
| NCT07037277 | phase3 | active_not_recruiting | 2025-06-02 | 2026-12-01 | Atea Pharmaceuticals, Inc. | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV |
| NCT07314346 | phase1 | recruiting | 2025-01-07 | 2026-08-01 | Atea Pharmaceuticals, Inc. | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone |
FDA applications (0)
No records yet.